JP2012526844A - Mciおよびアルツハイマー病の処置 - Google Patents

Mciおよびアルツハイマー病の処置 Download PDF

Info

Publication number
JP2012526844A
JP2012526844A JP2012511013A JP2012511013A JP2012526844A JP 2012526844 A JP2012526844 A JP 2012526844A JP 2012511013 A JP2012511013 A JP 2012511013A JP 2012511013 A JP2012511013 A JP 2012511013A JP 2012526844 A JP2012526844 A JP 2012526844A
Authority
JP
Japan
Prior art keywords
nifedipine
therapeutically effective
effective amount
nitrosonifedipine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012511013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526844A5 (cg-RX-API-DMAC7.html
Inventor
マーク ラベル,
バート リン,
Original Assignee
ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション filed Critical ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション
Publication of JP2012526844A publication Critical patent/JP2012526844A/ja
Publication of JP2012526844A5 publication Critical patent/JP2012526844A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012511013A 2009-05-15 2010-05-13 Mciおよびアルツハイマー病の処置 Pending JP2012526844A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21645209P 2009-05-15 2009-05-15
US61/216,452 2009-05-15
US23455109P 2009-08-17 2009-08-17
US61/234,551 2009-08-17
PCT/US2010/034721 WO2010132671A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2012526844A true JP2012526844A (ja) 2012-11-01
JP2012526844A5 JP2012526844A5 (cg-RX-API-DMAC7.html) 2013-06-27

Family

ID=43069025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012511013A Pending JP2012526844A (ja) 2009-05-15 2010-05-13 Mciおよびアルツハイマー病の処置

Country Status (7)

Country Link
US (1) US20100292281A1 (cg-RX-API-DMAC7.html)
EP (1) EP2429992A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012526844A (cg-RX-API-DMAC7.html)
AU (1) AU2010249015A1 (cg-RX-API-DMAC7.html)
CA (1) CA2761298A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011012015A (cg-RX-API-DMAC7.html)
WO (1) WO2010132671A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005276117C1 (en) 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
LT1937244T (lt) 2005-09-30 2018-11-12 Io Therapeutics, Llc Vėžio gydymas specifiniais rxr agonistais
EP3263127B1 (en) 2011-05-23 2019-08-21 Yeda Research and Development Co. Ltd Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2013022953A2 (en) * 2011-08-08 2013-02-14 Eugenia Wang Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
MX2014015310A (es) * 2012-06-15 2015-07-06 Found Biomedical Res & Innov Agente profilactico y/o terapeutico para el deterioro cognoscitivo leve.
US8901305B2 (en) * 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
KR102149321B1 (ko) * 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
KR102549273B1 (ko) 2016-03-10 2023-06-28 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
NZ745704A (en) 2016-03-10 2019-04-26 Io Therapeutics Inc Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
EP3684348A4 (en) * 2017-09-20 2021-08-18 IO Therapeutics, Inc. TREATMENT OF DISEASES WITH ETERS FROM SELECTIVE RXR AGONISTS
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
EP4444287A4 (en) 2021-12-07 2025-05-28 Io Therapeutics, Inc. USE OF AN RXR AGONIST AND TAXANES FOR THE TREATMENT OF HER2+ CANCER

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110354A2 (en) * 2003-05-15 2004-12-23 Roskamp Research, Llc Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
WO2006109164A2 (en) * 2005-04-15 2006-10-19 Research & Innovation Soc. Coop. A R.L. A method for preventing, delaying or reverting abnormal amyloid deposition
JP2007091664A (ja) * 2005-09-29 2007-04-12 Univ Of Tokushima 細胞膜保護剤
JP2007512338A (ja) * 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション L型カルシウムチャンネルブロッカーとコリンエステラーゼ阻害剤を用いた組成物及び処置方法
WO2007064010A1 (ja) * 2005-12-02 2007-06-07 Mochida Pharmaceutical Co., Ltd. アルツハイマー型認知症予防・治療剤
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
JP2009073759A (ja) * 2007-09-20 2009-04-09 Univ Of Tokushima Icam−1発現抑制剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
DE4342196A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Neue 4-Phenyl-substituierte 1,4-Dihydropyridine
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
WO1999043307A1 (en) * 1998-02-26 1999-09-02 Prange Arthur J Jr Thyroid hormone replacement using sustained release triiodothyronine
EP1069918A4 (en) * 1998-04-08 2002-02-20 Univ Oregon Health Sciences ACTIVATION OF THE CELLULAR RECORDING OF THE GALLIUM
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US20080194494A1 (en) * 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110354A2 (en) * 2003-05-15 2004-12-23 Roskamp Research, Llc Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
JP2007512338A (ja) * 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション L型カルシウムチャンネルブロッカーとコリンエステラーゼ阻害剤を用いた組成物及び処置方法
WO2006109164A2 (en) * 2005-04-15 2006-10-19 Research & Innovation Soc. Coop. A R.L. A method for preventing, delaying or reverting abnormal amyloid deposition
JP2007091664A (ja) * 2005-09-29 2007-04-12 Univ Of Tokushima 細胞膜保護剤
WO2007064010A1 (ja) * 2005-12-02 2007-06-07 Mochida Pharmaceutical Co., Ltd. アルツハイマー型認知症予防・治療剤
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
JP2009073759A (ja) * 2007-09-20 2009-04-09 Univ Of Tokushima Icam−1発現抑制剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5012013695; JAVIDNIA: 'PHOTOSTABILITY DETERMINATION OF COMMERCIALLY AVAILABLE NIFEDIPINE ORAL DOSAGE FORMS IN IRAN' IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH V2 N2, 2003, P111-115 *
JPN6012058681; 堀ノ内裕也ら: 'Nifedipine代謝物の細胞保護効果の検討' 日本循環薬理学会口演要旨集 vol.16, 2006, p.60 *
JPN6014021496; 小川聡ら、病院薬学、1990年、16巻3号、189-197頁 *
JPN6014021497; P.Pietta, et al., Journal of Chromatography, 1981, 210(3), pp516-21 *

Also Published As

Publication number Publication date
CA2761298A1 (en) 2010-11-18
US20100292281A1 (en) 2010-11-18
WO2010132671A1 (en) 2010-11-18
AU2010249015A1 (en) 2011-11-24
EP2429992A1 (en) 2012-03-21
EP2429992A4 (en) 2012-11-28
MX2011012015A (es) 2012-04-30

Similar Documents

Publication Publication Date Title
JP2012526844A5 (cg-RX-API-DMAC7.html)
US20100292281A1 (en) Treatment of mci and alzheimer's disease
JP2013526518A (ja) Mciおよびアルツハイマー病の処置
US20200338040A1 (en) Methods for treating alzheimer's disease and related disorders
EP1383465B1 (en) Acute pharmacologic augmentation of psychotherapy with d-cycloserine
US9968574B2 (en) Treatment of MCI and Alzheimer's disease
AU2017383127B2 (en) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
TW202425995A (zh) 減少與神經退化疾病相關的神經退化的方法
JP2010531854A (ja) 抗アミロイド剤としてのピレンゼピンおよびその誘導体
JP4971794B2 (ja) アミロイド沈積、アミロイド神経毒性およびミクログリオーシスを低減する方法
CN101883564B (zh) 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
Lovell et al. Treatment of MCI and Alzheimer's Disease
Samentar et al. A novel hybrid protein promotes Aβ clearance and reduces inflammatory response through MerTK
CN120131965A (zh) Glp-1受体激动剂治疗阿尔茨海默病的用途
KR20130030011A (ko) 뇌손상에 의한 전두엽 기능장애 모델 동물 및 전두엽 기능장애의 개선용 조성물
Cavanagh The Role of Tumor Necrosis Factor-α in a Prodromal Mouse Model of Alzheimer's Disease
Ranade et al. TARGET EVOLUTION AND THERAPY ADVANCEMENTS FOR ALZHEIMER’S DISEASE: A REVIEW
HK1212603A1 (zh) 治疗阿尔茨海默病及相关疾病的组合疗法

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141120